Posts Tagged ‘Pear Therapeutics’
Pear Therapeutics raises $80M; finds cost savings of $2,150 per patient with opioid use disorder
Pear Therapeutics raises $80M in push for reimbursement (MedCity News): Pear Therapeutics raised $80 million in funding, which it plans to use as part of a push for coverage of its digital therapeutics. The Boston-based company has three FDA-cleared products, including digital therapeutics for substance use disorder, opioid use disorder, and most recently, insomnia.
Read MoreThe FDA clears Somryst, Pear’s digital therapeutic to treat chronic insomnia
Pear gets FDA clearance for insomnia therapeutic (MedCity News): “Pear Therapeutics received marketing authorization for its third product — a digital therapeutic intended to treat chronic insomnia. Called Somryst, the app is available by prescription only. It consists of a nine-week program that includes cognitive behavioral therapy and restricting sleep to a limited window of time
Read MoreOn Awe, Healthy Eating, Mental Health, Ethical Neurotech, and more
_____ Time to wrap-up another very active month with our SharpBrains e‑newsletter summarizing exciting developments in brain research, healthcare and technology — plus a couple fun brain teasers to spark curiosity and innovation :-) New brain research: Brain scans shed light on the brain networks supporting Awe For World Mental Health Day let’s review how a healthy…
Read MoreNovartis dissolves agreement to market Pear Therapeutics’ prescription digital therapeutics for substance/ opioid abuse
_______________ As Sandoz returns marketing rights for digital therapeutics to Pear, what does it mean for co-promote arrangements? (MM&M): “Sandoz, the generics division of Novartis, is altering commercial course, returning marketing duties for two prescription digital therapeutics (DTx) back to Pear Therapeutics. The move, which some had anticipated, comes 18 months after the two signed…
Read MoreTrend: Pharma industry warming up to digital therapeutics
Digital therapeutics have potential but commercial success unproven (Vantage): “Developing drugs to treat disorders of the central nervous system is famously fraught with difficulty. Several companies, including Pear Therapeutics and Dthera, are taking a wildly different approach: digital therapeutics. These are pieces of software designed to treat disease that are regulated, prescribed and even paid…
Read MoreCan digital Cognitive Behavioral Therapy (CBTi) become the universal first-line treatment for insomnia?
__________ Pear Therapeutics’ digital insomnia therapeutic will put FDA’s PreCert framework through its paces (MobiHealthNews): “Prescription digital therapeutics company Pear Therapeutics announced late last week that it has filed an FDA marketing authorization for Somryst, its digital cognitive behavioral therapy for the treatment of adults with chronic insomnia and depression. While an approval from the…
Read More